, Volume 168, Supplement 1, pp 445–453

The use of transdermal nicotine in smoking cessation


  • Ph. Müller
    • Clinical Pharmacology, Pharmaceutical DivisionCIBA-GEIGY Ltd.
  • Th. Abelin
    • Department of Preventive MedicineUniversity of Berne
  • R. Ehrsam
    • Department of Physical EducationUniversity of Basle
  • P. Imhof
    • Clinical Pharmacology, Pharmaceutical DivisionCIBA-GEIGY Ltd.
  • H. Howald
    • Clinical Pharmacology, Pharmaceutical DivisionCIBA-GEIGY Ltd.
  • D. Mauli
    • Clinical Pharmacology, Pharmaceutical DivisionCIBA-GEIGY Ltd.
Smoke-Free Europe In The Year 2000

DOI: 10.1007/BF02718163

Cite this article as:
Müller, P., Abelin, T., Ehrsam, R. et al. Lung (1990) 168: 445. doi:10.1007/BF02718163


The transdermal administration of nicotine by means of a transdermal nicotine system (TNS) affords a novel way of nicotine replacement to alleviate smoking cessation. The plasma levels of nicotine maintained with the TNS are in the range of the footpoint concentrations observed in smokers. The efficacy of the TNS was investigated in two placebo-controlled double-blind smoking cessation programs with minimal contact and minimal psychological support. A total of 311 smokers were treated for 3 months or 9 weeks. The abstinence rates at the end of the treatment and weaning periods were almost doubled in the TNS groups (36% and 39%) as compared to the placebo groups (23% and 20%) with a significant difference for both studies (p<0.05). These data suggest that the TNS can also improve the smoking cessation rates under the conditions of general medical advice, making it suitable for use outside of specialized smoking cessation centers.

Key words

Transdermal administration of nicotineSmoking cessationMinimal psychological supportWeaning periodsAbstinence rates

Copyright information

© Springer-Verlag New York Inc 1990